Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3722 - Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Translational Research


Samuel Klempner


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


S.J. Klempner1, G.M. Frampton2, J. Chao3, M. Bailey4, P. Stephens5, J.S. Ross6, V.A. Miller7, S.M. Ali8, A.B. Schrock5

Author affiliations

  • 1 Medical Oncology, The Angeles Clinic and Research Institute, 90025 - Los Angeles/US
  • 2 Oncology, Foundation Medicine, 02141 - Cambridge/US
  • 3 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 4 Oncology, Foundation Medicine, MA 02141 - Cambridge/US
  • 5 R & D, Foundation Medicine, MA 02141 - Cambridge/US
  • 6 Pathology, Albany Medical Center, 12208 - Albany/US
  • 7 Medical Affairs, Foundation Medicine, MA 02141 - Cambridge/US
  • 8 Clinical Development, Foundation Medicine, MA 02141 - Cambridge/US


Abstract 3722


Response to immune checkpoint inhibitors (ICPIs) is mediated in part by tumor neoantigens. TMB has emerged as a predictive biomarker, but data is lacking in GIm. We examined TMB and concurrent GA across GIm to identify patient subsets for further study.


Comprehensive genomic profiling was used to determine TMB, microsatellite instability (MSI), and additional GA using previously described methods. GA were compared among anatomically defined tumor types and stratified by TMB status (mutations/DNA megabase), and those associated with response or resistance to ICPIs were compared to identify patient subsets.


Median TMB was higher for tubular vs. non-tubular GIm (p = 0.032). Among the entire cohort, 3.5% and 7.4% of samples had a TMB >20 and >10, respectively. The proportion of tumors with TMB ≥10 was greatest within tubular foregut structures (esophagus, stomach, duodenum; 11.2%). MSI was observed across all anatomic subtypes (range: 0.2-6%). Overall 1.2% of cases harbored receptor tyrosine kinase (RTK) fusions; colon and biliary tumors with RTK fusions had high (11) and low (2.5) median TMB, respectively. Validated immunoresponsive GA including PD-L1 amplification and POLE mutations were mutually exclusive and enriched in tubular GI structures [esophagus (0.5%), stomach (0.8%), colon (0.9%), duodenum (1.3%) and rectum (0.9%)]. POLE mutation, but not PD-L1 amplification, correlated with high TMB (median 100 and 5.4, respectively). PIK3CA catalytic (H1047R) vs. helical (E545K) domain GA were strongly associated with high TMB (p 


GAs associated with increased sensitivity and/or resistance to ICPIs are observed across GI cancers. Baseline genomic profling may inform rational patient selection for immunotherapy treatment. The observation that high TMB and MSI are strongly enriched for PIK3CA H1047R, and whereas low TMB and MSS are enriched for E545K, warrants further study.

Clinical trial identification

Legal entity responsible for the study

Samuel J. Klempner




S.J. Klempner: Honoraria - Foundation Medicine, Inc Advisory/Consulting - Lilly Oncology, Pfizer, Boston Biomedical. G.M. Frampton, M. Bailey, P. Stephens, J.S. Ross, V.A. Miller, S.M. Ali, A.B. Schrock: Employment - Foundation Medicine, Inc. J. Chao: Advisory/Consulting - Lilly Oncology, Boston Biomedical Research Funding – Merck.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.